torsemide has been researched along with bumetanide in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 7 (26.92) | 24.3611 |
| 2020's | 3 (11.54) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delarge, J; Ferrandi, M; Ferrari, P; Masereel, B; Parenti, P; Pirotte, B; Schynts, M | 1 |
| Brater, DC | 1 |
| Brater, DC; Gehr, TW; Kramer, WG; Matzke, GR; Rudy, DW; Sica, DA | 1 |
| Silke, B | 1 |
| Chen, BP | 1 |
| Kelso, E; McDermott, B; Silke, B; Spiers, P | 1 |
| Bard, RL; Bleske, BE; Nicklas, JM | 1 |
| Eshaghian, S; Fonarow, GC; Horwich, TB | 1 |
| Chuen, MJ; MacFadyen, RJ | 1 |
| Brockmöller, J; Meineke, I; Nürnberg, P; Schirmer, M; Sehrt, D; Toliat, MR; Tzvetkov, M; Vormfelde, SV | 1 |
| Cantarovich, F; Hoste, E; Mehta, RL; Murray, P; Shaw, A | 1 |
| Baughman, KL; Desai, AS; Fang, JC; Givertz, MM; Lewis, EF; Mielniczuk, LM; Nohria, A; Stevenson, LW; Tsang, SW | 1 |
| Bloomfield, DM; Cleland, JG; Cotter, G; Damman, K; Davison, B; Dittrich, HC; Fiuzat, M; Givertz, MM; Hillege, HL; Massie, BM; Metra, M; O'Connor, CM; Ponikowski, P; Teerlink, JR; Valente, MA; Van Veldhuisen, DJ; Voors, AA | 1 |
| Brockmöller, J; Dalila, N; Haubrock, M; Schirmer, M; Tzvetkov, MV; Vormfelde, SV | 1 |
| Agewall, S; Atar, D; Clark, AL; Cleland, JGF; Frankenstein, L; Fröhlich, H; Goode, K; Grundtvig, M; Hole, T; Katus, HA; Kazmi, S; Schellberg, D; Seiz, M; Täger, T | 1 |
| Gramer, M; Hampel, P; Löscher, W; Römermann, K | 1 |
| Gailus, B; Gericke, B; Hampel, P; Johne, M; Kaczmarek, E; Löscher, W; Römermann, K | 1 |
| Gramer, M; Kirchhoff, L; Löscher, W; Schmidt, R; Welzel, B | 1 |
5 review(s) available for torsemide and bumetanide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical pharmacology of loop diuretics.
Topics: Bumetanide; Diuretics; Furosemide; Humans; Sulfonamides; Torsemide | 1991 |
Central hemodynamic effects of diuretic therapy in chronic heart failure.
Topics: Bumetanide; Cardiac Output; Diuresis; Diuretics; Furosemide; Heart Failure; Hemodynamics; Humans; Muzolimine; Plasma Volume; Sulfonamides; Torsemide | 1993 |
Loop diuretics: comparison of torsemide, furosemide, and bumetanide.
Topics: Bumetanide; Diuretics; Furosemide; Humans; Sulfonamides; Torsemide | 1996 |
Food: an unrecognized source of loop diuretic resistance.
Topics: Administration, Oral; Area Under Curve; Bumetanide; Clinical Trials as Topic; Diuresis; Diuretics; Food; Furosemide; Humans; Intestinal Absorption; Sulfonamides; Torsemide | 2004 |
4 trial(s) available for torsemide and bumetanide
| Article | Year |
|---|---|
The pharmacodynamics of intravenous and oral torsemide in patients with chronic renal insufficiency.
Topics: Administration, Oral; Bumetanide; Diuretics; Double-Blind Method; Furosemide; Humans; Injections, Intravenous; Kidney Failure, Chronic; Sulfonamides; Torsemide | 1994 |
Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs.
Topics: Adult; Bumetanide; Cross-Over Studies; Diuretics; Epithelial Sodium Channels; Furosemide; Genotype; Haplotypes; Humans; Kidney; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Potassium; Receptors, Drug; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 1; Solute Carrier Family 12, Member 3; Sulfonamides; Symporters; Thiazides; Torsemide | 2007 |
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
Topics: Acute Disease; Aged; Analysis of Variance; Atherosclerosis; Bumetanide; Diabetes Complications; Diuretics; Dose-Response Relationship, Drug; Drug Resistance; Dyspnea; Female; Furosemide; Heart Failure; Humans; Hypotension; Male; Patient Readmission; Renal Insufficiency; Sulfonamides; Torsemide; Treatment Outcome; Weight Loss; Xanthines | 2014 |
Impact of mineralocorticoid receptor polymorphisms on urinary electrolyte excretion with and without diuretic drugs.
Topics: Adolescent; Adult; Bumetanide; Cross-Over Studies; Diuretics; Electrolytes; Furosemide; Genetic Association Studies; Humans; Hydrochlorothiazide; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Potassium; Receptors, Mineralocorticoid; Single-Blind Method; Sodium Chloride; Sulfonamides; Torsemide; Triamterene; Young Adult | 2015 |
17 other study(ies) available for torsemide and bumetanide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Na+,2Cl-,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives.
Topics: Animals; Blood Pressure; Bumetanide; Chlorine; Diuretics; Erythrocytes; Hypertension; In Vitro Techniques; Kidney Medulla; Male; Potassium; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Rubidium Radioisotopes; Sodium; Structure-Activity Relationship; Sulfonamides; Torsemide | 1992 |
Positive effect of bumetanide on contractile activity of ventricular cardiomyocytes.
Topics: Animals; Bumetanide; Calcium Channels, L-Type; Cardiotonic Agents; Diuretics; Furosemide; Heart Ventricles; Isoproterenol; Male; Myocardial Contraction; Rabbits; Sulfonamides; Torsemide | 2000 |
Relation of loop diuretic dose to mortality in advanced heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bumetanide; California; Creatinine; Diuretics; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Sulfonamides; Survival Analysis; Torsemide | 2006 |
Dose-dependent association between use of loop diuretics and mortality in advanced systolic heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bumetanide; California; Creatinine; Diuretics; Dose-Response Relationship, Drug; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume; Sulfonamides; Survival Analysis; Torsemide; Ventricular Dysfunction, Left | 2006 |
Pharmacologic approaches for volume excess in acute kidney injury (AKI).
Topics: Acute Kidney Injury; Ascites; Bumetanide; Diuretics; Fluid Therapy; Furosemide; Heart Failure; Hepatorenal Syndrome; Humans; Kidney; Kidney Failure, Chronic; Liver Cirrhosis; Natriuretic Agents; Nephrotic Syndrome; Renal Replacement Therapy; Sodium Potassium Chloride Symporter Inhibitors; Sulfonamides; Torsemide; Ultrafiltration; Water-Electrolyte Imbalance | 2008 |
The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients.
Topics: Ambulatory Care; Ambulatory Care Facilities; Antihypertensive Agents; Bumetanide; Comorbidity; Diuretics; Female; Furosemide; Health Status Indicators; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sulfonamides; Torsemide; Treatment Outcome | 2008 |
Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - A multicenter propensity score matched analysis.
Topics: Aged; Blood Pressure; Bumetanide; Cause of Death; Europe; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Male; Middle Aged; Propensity Score; Retrospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Survival Rate; Torsemide; Treatment Outcome; Ventricular Function, Left | 2019 |
The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
Topics: Animals; Brain; Bumetanide; Endothelial Cells; Humans; Mice; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Sulfanilamides; Torsemide | 2021 |
Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Topics: Animals; Anticonvulsants; Bumetanide; Drug Therapy, Combination; Epilepsy; Female; Mice; Phenobarbital; Pilocarpine; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Sulfanilamides; Torsemide; Treatment Outcome | 2021 |
The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Topics: Animals; Asphyxia; Bumetanide; Diuretics; Epilepsy; Furosemide; Rats; Sodium Potassium Chloride Symporter Inhibitors; Solute Carrier Family 12, Member 2; Torsemide | 2023 |